Hospital-acquired and ventilator-associated pneumonia account for 22% of all hospital-acquired infections.
Two recently approved agents offer significant activity against these hard-to-treat conditions.
Care continues to improve; however, drug-resistant pathogens and a lack of new agents to treat these infections remain a constant challenge.
This article highlights some key updates to the antimicrobial therapy recommendations in the updated community-acquired pneumonia guidelines.
Hepatitis C virus is the world’s most prevalent blood-borne viral infection for which a vaccine does not exist. To eliminate HCV infection on a global scale, experts argue that vaccine development needs to become a public health priority.
Eravacycline is an antibiotic that has been touted for possible treatment of difficult-to-treat resistant (DTR) Gram-negative infections. But can it tackle carbapenem-resistant Acinetobacter baumannii (CRAB) infections?
Infections caused by non–carbapenemase-producing carbapenem-resistant Enterobacteriaceae present challenges in the treatment paradigm. Given the limited clinical data, the preferred therapeutic approach remains unknown.
Expanding the differential for diarrhea beyond Clostridium difficile.
Exploring the antibiotic commercial conundrum. ​
The impact of viruses on community-acquired pneumonia seems to be greater than initially realized and the use of procalcitonin may help distinguish infection type for appropriate treatment.
This orphan drug is for patients with limited antiretroviral treatment options.
Patients with Lyme disease know that their symptoms and the effects of the disease can be debilitating and last for a long time, often persisting even after treatment.
A recent UNC study found that about one-third of HIV-positive patients with low viral loads chose to ignore federal guidelines to begin ART.
In addition to other updates, new breakpoints have been added for cefiderocol and meropenem-vaborbactam.
This highlighted study looks at using these 2 therapies concurrently for this infection.
BNT162b1, a SARS-CoV-2 vaccine candidate, elicited promising early signs of immune activity in a placebo-controlled phase 1/2 study.
Advances in antiretroviral therapies increase opportunities for patients with HIV to have more successful treatment outcomes.
Alzheimer’s disease, dementia, and genetic variations in areas key to viral infection are risk factors for severe COVID-19 a new study suggests.
Expanding the differential for diarrhea beyond Clostridium difficile.
Because of the global rise in antimicrobial resistance, meropenem-vaborbactam, the first carbapenem/β-lactamase combina­tion medication, is a welcome new antibac­terial.
Texas could be the site of the next large measles outbreak in the United States, according to a new study that highlights the low vaccination rates among schools there.
This is one of the first studies examining the effect of a dedicated postsplenectomy comprehensive clinic.
Experts weigh in on what Congress is doing to tackle the threat of antibiotic resistance.
The health system’s response could be used as a teaching model for addressing future infectious disease threats.
For all you last-minute shoppers, Payal K. Patel MD, MPH, and Sujit Suchindran MD, have put together a wish list of the top items to get the infectious disease physician in your life.
Women living with HIV are at elevated risk for comorbidities as their life expectancy increases.
By stopping unnecessary antibiotics before they start, clinicians can avoid unnecessary harm to the patient and the population.
Rising incidence of viral and bacterial infections has accompanied the opioid crisis, but it also presents new opportunities for multidisciplinary treatment and preventive care.